Ultrix Quadri

2019: Start of production Ultrix Quadri

The joint venture "Nacimbio" State corporations Rostec and Marathon Group – the plant "FORT" – begins production of tetravalent vaccine against flu of Ultriks Kvadri. On July 22, 2019 Marathon Group reported about it. Medicine for immunization of adults successfully was registered century Ministry of Health Russia. Medicine will go on sale in August, 2019.

"Ultriks Kvadri" four relevant strains of viruses of flu instead of three – A(H1N1), A(H3N2) and two strains of viruses of flu of group B include. According to the recommendations of World Health Organization, medicine contains about 15 mkg of a gemagglyutinin (antigen) of each strain in one dose – only 60 mkg of antigen. Vaccine is safe, considerably reduces risk of incidence and promotes formation of resistant immunity. Results of clinical trials during which were revealed high concentration of antibodies to all types of viruses of flu which are a part of medicine demonstrate to it.

Vaccine corresponds to all WHO recommendations and world pharmaceutical trends, it is the first Russian medicine of such structure for prevention of flu. During creation of this vaccine preservatives, adjuvants and immunomodulators are not used. It is planned that medicine will come to the market in August, 2019 and it will be available to vaccination of adults from 18 years within the national calendar of preventive inoculations. In the long term Ultriks Kvadri is urged to become mass vaccine and to replace medicines of the previous generation, told Sergey Chemezov, the CEO of State Corporation Rostec

"Ultriks Kvadri" it will be made on technology of a full stroke with observance of the GMP standards at the FORT plant in the Ryazan region. In the long term the enterprise is going to increase annual production volume to 50 million doses for implementation both on internal, and in foreign markets. Medicine will be produced in the prefilled syringes.

Both the trivalent vaccine "Ultriks", and the provided kvadrivalentny vaccine completely are manufactured in Russia, including an antigen operating time. This key difference of our vaccine from analogs. We are glad that we can offer the Russian health care system a hi-tech product of the last generation for immunization of our compatriots, and we will continue work on expansion of a line of vaccines available to Russians for prevention of different diseases, comments Alexander Vinokurov, the president of Marathon Group

Tetravalent vaccines protect from an infection more effectively as allow to exclude the possible risks connected with emergence and circulation of the Victorian and Yamagata lines of viruses of flu of group B. For July, 2019 about 70% of the vaccines applied in the USA are tetravalent, in Japan their share reaches 100%.

2017: Beginning of development of the vaccine "Ultriks Kvadri"

Development of the vaccine "Ultriks Kvadri" began in 2017, then recommended to WHO kvadrivalentny vaccines for application around the world.